Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandro Ardizzone

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Journal of Crohn'S & Colitis|March 28, 2020
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?Giovanni Monteleone, Sandro Ardizzone
Drugs|November 4, 2005
Biologic therapy for inflammatory bowel diseaseSandro Ardizzone, Gabriele Bianchi Porro
Drug Safety|July 13, 2002
Comparative tolerability of therapies for ulcerative colitisSandro Ardizzone, Gabriele Bianchi Porro
Therapeutic Advances in Gastroenterology|July 2, 2016
Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's diseaseSandro Ardizzone, Gerolamo Bevivino, Giovanni Monteleone
World Journal of Gastrointestinal Endoscopy|March 29, 2019
Endoscopic retrograde cholangiopancreatography, lights and shadows: Handle with careRaffaele Salerno, Nicolò Mezzina, Sandro Ardizzone
Biologics : Targets & Therapy|August 27, 2009
Biologic targeting in the treatment of inflammatory bowel diseasesMatteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro
Core Evidence|January 12, 2011
Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseAndrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro
Expert Opinion on Emerging Drugs|November 21, 2012
Immunosuppressive and biologic therapy for ulcerative colitisSandro Ardizzone, Andrea Cassinotti, Roberto de Franchis
Biologics : Targets & Therapy|August 27, 2009
Adalimumab for the treatment of Crohn's diseaseAndrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro
Cancers|January 21, 2023
Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical ChallengeFrancesca Ferretti, Rosanna Cannatelli, Giovanni Maconi, et al.
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Journal of Crohn'S & Colitis|March 28, 2020
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?Giovanni Monteleone, Sandro Ardizzone
Drugs|November 4, 2005
Biologic therapy for inflammatory bowel diseaseSandro Ardizzone, Gabriele Bianchi Porro
Drug Safety|July 13, 2002
Comparative tolerability of therapies for ulcerative colitisSandro Ardizzone, Gabriele Bianchi Porro
Therapeutic Advances in Gastroenterology|July 2, 2016
Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's diseaseSandro Ardizzone, Gerolamo Bevivino, Giovanni Monteleone
World Journal of Gastrointestinal Endoscopy|March 29, 2019
Endoscopic retrograde cholangiopancreatography, lights and shadows: Handle with careRaffaele Salerno, Nicolò Mezzina, Sandro Ardizzone
Biologics : Targets & Therapy|August 27, 2009
Biologic targeting in the treatment of inflammatory bowel diseasesMatteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro
Core Evidence|January 12, 2011
Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseAndrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro
Expert Opinion on Emerging Drugs|November 21, 2012
Immunosuppressive and biologic therapy for ulcerative colitisSandro Ardizzone, Andrea Cassinotti, Roberto de Franchis
Biologics : Targets & Therapy|August 27, 2009
Adalimumab for the treatment of Crohn's diseaseAndrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro
Cancers|January 21, 2023
Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical ChallengeFrancesca Ferretti, Rosanna Cannatelli, Giovanni Maconi, et al.
Pageof 16